Just caught the earnings report from BillionToOne and it's quite a turnaround story worth paying attention to. The molecular diagnostics company just posted Q4 results that swung into profitability with $4.4 million in net income, a stark contrast to the $11.5 million loss they had a year ago. What's really striking is the 113% revenue growth hitting $96.1 million in the quarter.

The numbers tell an interesting story about execution. Revenue per test (ASP) jumped 47% while they also delivered 47% more tests overall, hitting $561 per test. Both their prenatal and oncology divisions showed solid momentum quarter-over-quarter and year-over-year. For the full year 2025, they posted $2.9 million in net income on $305.1 million in revenue, which represents 100% growth compared to the prior year. That's the kind of scaling you rarely see in this space.

What caught my eye is their balance sheet position. They're sitting on roughly $496 million in cash and cash equivalents, which gives them real runway to execute on their strategy. And the forward guidance suggests management is confident about the trajectory. They're raising 2026 full-year revenue guidance to $430-445 million, implying 41-46% growth, and they're expecting positive operating income for the full year. That's a meaningful upgrade from their previous guidance.

Looking at their product portfolio, the company's been pushing innovation pretty aggressively. Their UNITY Complete prenatal screening product is getting expanded with new fetal antigen offerings, including what they claim are the first and only non-invasive prenatal tests in the U.S. designed to determine fetal antigen status across red blood cell and platelet antigens. These new offerings specifically address conditions like Hemolytic Disease of the Fetus and Newborn and neonatal alloimmune thrombocytopenia, which are serious complications that doctors have been looking for better screening solutions for.

On the oncology side, they've been rolling out add-on applications for their Northstar Select liquid biopsy platform. The new Northstar PGx application reports metabolizer status to help with treatment planning, while Northstar Select CH addresses clonal hematopoiesis, which has been a known source of false positives in circulating free DNA testing. The sensitivity on their Northstar Response assay is impressive too—detecting tumor burden down to 0.01% fraction.

The CEO's commentary about scaling their differentiated platform in 2026 seems backed by real momentum. Their ultra-sensitive oncology assays and the expansion into prenatal screening with neonatal alloimmune thrombocytopenia detection capabilities position them well in a market that's increasingly moving toward precision diagnostics.

Stock-wise, BLLN closed the day at $80.83, down 2.78%, but popped 2.31% in after-hours trading to $82.70. For context, the stock has ranged from $66 to $138.70 over the past year. Interesting to see how the market processes this beat and raise against their execution track record.